News
LCTX
0.6949
+1.45%
0.0099
Weekly Report: what happened at LCTX last week (0210-0214)?
Weekly Report · 10h ago
Lineage Therap Issues Private Placement Securities
TipRanks · 4d ago
Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
Benzinga · 6d ago
Promising Advancements in Lineage’s OPC1 Program Boost Investor Confidence
TipRanks · 6d ago
Lineage Cell Therapeutics Price Target Cut to $2.00/Share From $3.00 by D. Boral Capital
Dow Jones · 6d ago
Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 6d ago
Lineage Cell Therapeutics initiates study of OPC1 for spinal injury
TipRanks · 6d ago
Weekly Report: what happened at LCTX last week (0203-0207)?
Weekly Report · 02/10 11:22
Weekly Report: what happened at LCTX last week (0127-0131)?
Weekly Report · 02/03 11:27
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics
Benzinga · 01/31 14:01
Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 01/31 12:49
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
Benzinga · 01/31 12:38
Promising Advancements in Cell Therapy: Lineage Cell Therapeutics Receives Buy Rating from Joseph Pantginis
TipRanks · 01/31 11:32
Lineage Therap Secures $66M Funding Through Direct Offering
TipRanks · 01/27 22:00
Weekly Report: what happened at LCTX last week (0120-0124)?
Weekly Report · 01/27 11:30
Weekly Report: what happened at LCTX last week (0113-0117)?
Weekly Report · 01/20 11:21
Lineage Cell Therapeutics Is Maintained at Buy by Maxim Group
Dow Jones · 01/10 18:36
Lineage Cell Therapeutics Price Target Cut to $3.00/Share From $5.00 by Maxim Group
Dow Jones · 01/10 18:36
Maxim Group Maintains Buy on Lineage Cell Therapeutics, Lowers Price Target to $3
Benzinga · 01/10 18:25
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.